These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 14560039)

  • 1. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity.
    Baylis C; Atzpodien EA; Freshour G; Engels K
    J Pharmacol Exp Ther; 2003 Dec; 307(3):854-60. PubMed ID: 14560039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
    Blanco S; Vaquero M; Gómez-Guerrero C; López D; Egido J; Romero R
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):557-65. PubMed ID: 15831368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.
    Schäfer S; Schmidts HL; Bleich M; Busch AE; Linz W
    Br J Pharmacol; 2004 Sep; 143(1):27-32. PubMed ID: 15289289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination.
    Renaud IM; Chainey A; Belair MF; Mandet C; Michel O; Myara I; Chevalier J; Plante GE
    Fundam Clin Pharmacol; 2004 Aug; 18(4):437-47. PubMed ID: 15312150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat.
    Schrijvers BF; Flyvbjerg A; Tilton RG; Lameire NH; De Vriese AS
    Nephrol Dial Transplant; 2006 Feb; 21(2):324-9. PubMed ID: 16249198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction.
    Nakano R; Kurosaki E; Shimaya A; Kajikawa S; Shibasaki M
    Eur J Pharmacol; 2006 Nov; 549(1-3):185-91. PubMed ID: 16989806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats.
    Pelzer T; Jazbutyte V; Arias-Loza PA; Segerer S; Lichtenwald M; Law MP; Schäfers M; Ertl G; Neyses L
    Biochem Biophys Res Commun; 2005 Apr; 329(2):726-32. PubMed ID: 15737646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
    Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats.
    Zhao X; Li LY
    Am J Nephrol; 2008; 28(4):598-606. PubMed ID: 18277067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.
    Kim SK; Zhao ZS; Lee YJ; Lee KE; Kang SM; Choi D; Lim SK; Chung N; Lee HC; Cha BS
    Diabetes Metab Res Rev; 2003; 19(6):487-93. PubMed ID: 14648808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
    Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
    Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model.
    Buléon M; Allard J; Jaafar A; Praddaude F; Dickson Z; Ranera MT; Pecher C; Girolami JP; Tack I
    Am J Physiol Renal Physiol; 2008 May; 294(5):F1249-56. PubMed ID: 18367657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats.
    Leehey DJ; Singh AK; Bast JP; Sethupathi P; Singh R
    Transl Res; 2008 Apr; 151(4):208-16. PubMed ID: 18355768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-peptide and captopril are equally effective in lowering glomerular hyperfiltration in diabetic rats.
    Samnegård B; Jacobson SH; Johansson BL; Ekberg K; Isaksson B; Wahren J; Sjöquist M
    Nephrol Dial Transplant; 2004 Jun; 19(6):1385-91. PubMed ID: 15004258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appropriateness of the Zucker Diabetic Fatty rat as a model for diabetic microvascular late complications.
    Hempe J; Elvert R; Schmidts HL; Kramer W; Herling AW
    Lab Anim; 2012 Jan; 46(1):32-9. PubMed ID: 22087029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
    Bilan VP; Salah EM; Bastacky S; Jones HB; Mayers RM; Zinker B; Poucher SM; Tofovic SP
    J Endocrinol; 2011 Sep; 210(3):293-308. PubMed ID: 21680617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
    Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
    Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.
    Gagliardini E; Corna D; Zoja C; Sangalli F; Carrara F; Rossi M; Conti S; Rottoli D; Longaretti L; Remuzzi A; Remuzzi G; Benigni A
    Am J Physiol Renal Physiol; 2009 Nov; 297(5):F1448-56. PubMed ID: 19675181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of temocapril on the prevention of early diabetic nephropathy in OLETF rat, an animal model for type 2 diabetes].
    Masuda H
    Hokkaido Igaku Zasshi; 2002 Sep; 77(5):419-28. PubMed ID: 12404757
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.